New Data from SPRAVATO™ (esketamine) CIII Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent - Yahoo Finance

Submitted by Anonymous (not verified) on Mon, 09/09/2019 - 13:00

New Data from SPRAVATO™ (esketamine) CIII Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent  Yahoo FinanceGlobal clinical program is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment studies TITUSVILLE, N.J. ...